ClinicalTrials.gg
CompletedNCT01342913Updated Aug 31, 2018Results posted

A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))

A Phase 3 interventional study of Fluticasone Furoate 100mcg/Vilanterol 25mcg and Fluticaosne Propionate 500mcg/Salmeterol 50mcg in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 66 sites in 9 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-08-31.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
528
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. fluticasone furoate · Pulmonary Disease, Chronic Obstructive.

Enrollment
8th of 25
528 · median 229
Started
2011
with 3 others
Phase 3
7 of 25
none open now
Registered
4th of 25
by date
Lead sponsor
21 of 25
GlaxoSmithKline

Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, this one is the 8th largest by enrollment, is one of 4 that started in 2011, is one of 7 in phase 3, and was the 4th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol 100/25mcg once daily compared with Salmeterol/Fluticasone Propionate 50/500mcg twice daily over a 12-week treatmen period in subjects with COPD.

Read the detailed description

This is a randomized, double-blind, double-dummy, multi-centre parallel group study. Subjects who meet the eligilibilty criteria at Screening and meet the randomization criteria at the end of a 2-week Run-In period will enter a 12-week Treatment period. There will be a 7-day Follow-up period after the treatment period.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated written
  • Male or females ≥ 40 years of age
  • Established clinical history of by ATS/ERS definition
  • Females are eligible to enter and participate if of non-, or if of child bearing potential, has a negative serum pregnancy test at screening, and agrees to one of the acceptable methods listed in protocol, used consistently and correctly
  • Former or current smoker > 10 pack years
  • Post-albuterol spirometry criteria: /FVC ratio ≤ 0.70 and FEV1 ≤ 70% of predicted normal (NHANES III)
  • have been hospitalised or have been treated with oral or antibiotics for their COPD within the last 3 years prior to Screening (Visit 1)

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of asthma
  • Subjects with other respiratory disorders including active tuberculosis, α1-antitrypsin deficiency, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
  • Lung volume reduction surgery within previous 12 months
  • abnormalities not due to by chest x-ray
  • Hospitalized for poorly controlled COPD within 12 weeks of Screening
  • Poorly controlled COPD 6 weeks prior to Screening, defined as acute worsening of COPD that is managed by the subject with or antibiotics or that requires treatment prescribed by a physician
  • Lower respiratory infection requiring antibiotics 6 weeks prior to Screening
  • Uncontrolled or clinically significant (in opinion of PI) cardiovascular, hypertension, neurological, psychiatric, renal, hepatic, immunological, endocrine, peptic ulcer disease, or hematological abnormalities
  • Carcinoma not in complete remission for at least 5 years
  • Subjects with history of to study medications (e.g., beta-agonists, corticosteroid) or components of inhalation powder (e.g., lactose, magnesium stearate)
  • Subjects with history of severe milk protein allergy that, in opinion of study physician, contraindicates subject's participation - Known/suspected history of alcohol or drug abuse in the last 2 years
  • Women who are pregnant or lactating or plan to become pregnant
  • Subjects medically unable to withhold albuterol and/or ipratropium 4 hours prior to spirometry testing at each study visit
  • Use of certain medications such as bronchodilators and corticosteroids for the protocol-specific times prior to Visit 1 (the Investigator will discuss the specific medications)
  • Long Term Oxygen Therapy (LTOT) or nocturnal oxygen therapy >12 hours a day
  • Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening or during the study - Non-compliance or inability to comply with study procedures or scheduled visits
  • Affiliation with investigator site
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
528 participants (actual)

Study arms

  • Experimental
    Fluticasone Furoate/Vilanterol

    Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA)

    Drug: Fluticasone Furoate 100mcg/Vilanterol 25mcg

  • Active comparator
    Fluticasone Propionate/Salmeterol

    Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA

    Drug: Fluticaosne Propionate 500mcg/Salmeterol 50mcg

Interventions

  • DrugFluticasone Furoate 100mcg/Vilanterol 25mcg

    Drug page: Fluticasone furoate

    Inhalation Powder

  • DrugFluticaosne Propionate 500mcg/Salmeterol 50mcg

    Inhalation Powder

06

What researchers measure

Primary outcomes

  1. Change From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 84

    Pulmonary function was measured by forced expiratory volume in one second (FEV1). The weighted mean was calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 4, 6, 8, 12, 13, 14, 16, 20, and 24 hours on Treatment Day 84. Baseline trough FEV1 was the mean of the two assessments made 30 and 5 minutes pre-dose on Treatment Day 1. Change from Baseline was calculated as the average of the Day 84 values minus the Baseline value.

    Time frame: Baseline and Day 84

Secondary outcomes

  1. Time to Onset on Treatment Day 1

    Time to onset on Treatment Day 1 is defined as the time to an increase of 100 milliliters (mL) from Baseline in FEV1. Time of onset was calculated over 0 to 4 hours (5 min, 15 min, 30 min, 60 min, 120 min, and 240 min) post-dose.

    Time frame: Day 1

  2. Change From Baseline in Trough FEV1 on Treatment Day 85

    Pulmonary function was measured by forced expiratory volume in one second (FEV1). Trough FEV1 was defined as the 24-hour FEV1 assessment, which was obtained on Day 85. Baseline is defined as the mean of the two assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1.Change from Baseline was calculated as the average of the Day 85 values minus the Baseline value.

    Time frame: Baseline and Day 85

07

Results

Posted Jul 30, 2013

Participant flow

2-week Run-in Period
Participant flow — 2-week Run-in Period
MilestonePlacebo + SalbutamolSalmeterol/FP 50/500 µg BIDFF/VI 100/25 µg QD
Started70200
Completed52800
Not completed17400
Withdrew: Inclusion/exclusion criteria not met6600
Withdrew: Physician decision600
Withdrew: Withdrawal by subject700
Withdrew: Adverse event200
Withdrew: Protocol violation500
Withdrew: Continuation criteria not met8800
Double-Blind Treatment Period
Participant flow — Double-Blind Treatment Period
MilestonePlacebo + SalbutamolSalmeterol/FP 50/500 µg BIDFF/VI 100/25 µg QD
Started0262266
Completed0246243
Not completed01623
Withdrew: Adverse event036
Withdrew: Lack of efficacy023
Withdrew: Protocol violation069
Withdrew: Lost to follow-up013
Withdrew: Physician decision020
Withdrew: Withdrawal by subject022

Outcome measures

PrimaryChange From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 84

Pulmonary function was measured by forced expiratory volume in one second (FEV1). The weighted mean was calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 4, 6, 8, 12, 13, 14, 16, 20, and 24 hours on Treatment Day 84. Baseline trough FEV1 was the mean of the two assessments made 30 and 5 minutes pre-dose on Treatment Day 1. Change from Baseline was calculated as the average of the Day 84 values minus the Baseline value.

Time frame:
Baseline and Day 84
Reported as:
Least squares mean · Liters
Change From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 84
LitersSalmeterol/FP 50/500 µg BIDFF/VI 100/25 µg QD
Change From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 840.108 ± 0.01450.130 ± 0.0148
Statistical analysis
  • Salmeterol/FP 50/500 µg BID vs FF/VI 100/25 µg QD · ANCOVA · p = 0.282 · Least squares mean difference: 0.022 · 95% CI -0.018 to 0.063
SecondaryTime to Onset on Treatment Day 1

Time to onset on Treatment Day 1 is defined as the time to an increase of 100 milliliters (mL) from Baseline in FEV1. Time of onset was calculated over 0 to 4 hours (5 min, 15 min, 30 min, 60 min, 120 min, and 240 min) post-dose.

Time frame:
Day 1
Reported as:
Median · Minutes
Time to Onset on Treatment Day 1
MinutesSalmeterol/FP 50/500 µg BIDFF/VI 100/25 µg QD
Time to Onset on Treatment Day 128 (5 to 240)16 (5 to 240)
SecondaryChange From Baseline in Trough FEV1 on Treatment Day 85

Pulmonary function was measured by forced expiratory volume in one second (FEV1). Trough FEV1 was defined as the 24-hour FEV1 assessment, which was obtained on Day 85. Baseline is defined as the mean of the two assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1.Change from Baseline was calculated as the average of the Day 85 values minus the Baseline value.

Time frame:
Baseline and Day 85
Reported as:
Least squares mean · Liters
Change From Baseline in Trough FEV1 on Treatment Day 85
LitersSalmeterol/FP 50/500 µg BIDFF/VI 100/25 µg QD
Change From Baseline in Trough FEV1 on Treatment Day 850.088 ± 0.01540.111 ± 0.0155

Adverse events

Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication until Follow-up (up to 12 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Salmeterol/FP 50/500 µg BID—3/262 (1.1%)30/262 (11.5%)
FF/VI 100/25 µg QD—6/266 (2.3%)32/266 (12%)
Most frequent serious events
Most frequent serious events
EventSalmeterol/FP 50/500 µg BIDFF/VI 100/25 µg QD
PneumoniaInfections and infestations2/2621/266
Atrial fibrillationCardiac disorders0/2622/266
SialoadenitisInfections and infestations1/2620/266
Infective exacerbation of chronic obstructive airways diseasInfections and infestations0/2621/266
Angina pectorisCardiac disorders0/2621/266
Coronary artery diseaseCardiac disorders0/2621/266
Food poisoningGastrointestinal disorders0/2621/266
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2621/266
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/2621/266
Most frequent other events
Most frequent other events
EventSalmeterol/FP 50/500 µg BIDFF/VI 100/25 µg QD
HeadacheNervous system disorders18/26220/266
NasopharyngitisInfections and infestations12/2628/266
Back painMusculoskeletal and connective tissue disorders3/26210/266

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Salmeterol/FP 50/500 µg BIDFF/VI 100/25 µg QDTotal
Mean62.9 ± 9.0763.0 ± 8.1062.9 ± 8.59
Sex: Female, Male
Sex: Female, Male(Participants)Salmeterol/FP 50/500 µg BIDFF/VI 100/25 µg QDTotal
Female415495
Male221212433
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Salmeterol/FP 50/500 µg BIDFF/VI 100/25 µg QDTotal
African American/African Heritage101
Asian-South East Asian Heritage5348101
White-Arabic/North African Hertage213
White/Caucasian/European Heritage206217423
08

Study locations

66 sites
  • GSK Investigational Site
    Bouge, 5004, Belgium
  • GSK Investigational Site
    Brussels, 1200, Belgium
  • GSK Investigational Site
    Bruxelles, 1070, Belgium
  • GSK Investigational Site
    Edegem, 2650, Belgium
  • GSK Investigational Site
    Genk, 3600, Belgium
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Gilly, 6060, Belgium
  • GSK Investigational Site
    Bethune Cedex, 62408, France
  • GSK Investigational Site
    Brest Cedex, 29609, France
  • GSK Investigational Site
    Lille, 59000, France
  • GSK Investigational Site
    Marseille Cedex 20, 13915, France
  • GSK Investigational Site
    Montpellier cedex 5, 34295, France
  • GSK Investigational Site
    Nice, 06002, France
  • GSK Investigational Site
    Pessac cedex, 33604, France
  • GSK Investigational Site
    Muenchen, Bayern 80809, Germany
  • GSK Investigational Site
    Frankfurt am Main, Hessen 60596, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60389, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30159, Germany
  • GSK Investigational Site
    Magdeburg, Sachsen-Anhalt 39112, Germany
  • GSK Investigational Site
    Delitzsch, Sachsen 04509, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01307, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04207, Germany
  • GSK Investigational Site
    Berlin, 10117, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Berlin, 10789, Germany
  • GSK Investigational Site
    Berlin, 14057, Germany
  • GSK Investigational Site
    Hamburg, 20253, Germany
  • GSK Investigational Site
    Benevento, Campania 82100, Italy
  • GSK Investigational Site
    Salerno, Campania 84100, Italy
  • GSK Investigational Site
    Roma, Lazio 00135, Italy
  • GSK Investigational Site
    Sesto S. Giovanni MI, Lombardia 20099, Italy
  • GSK Investigational Site
    Acquaviva Delle Fonti BA, Puglia 70021, Italy
  • GSK Investigational Site
    Pisa, Toscana 56124, Italy
  • GSK Investigational Site
    Perugia, Umbria 06156, Italy
  • GSK Investigational Site
    Cittadella PD, Veneto 35013, Italy
  • GSK Investigational Site
    Verona, Veneto 37134, Italy
  • GSK Investigational Site
    Jaro, Iloilo City, 5000, Philippines
  • GSK Investigational Site
    Lipa City, 4217, Philippines
  • GSK Investigational Site
    Quezon City, 1100, Philippines
  • GSK Investigational Site
    Quezon City, 1101, Philippines
  • GSK Investigational Site
    Bialystok, Poland
  • GSK Investigational Site
    Czestochowa, 42-200, Poland
  • GSK Investigational Site
    Lodz, 92-107, Poland
  • GSK Investigational Site
    Lodz, 93-329, Poland
  • GSK Investigational Site
    Ostrow Wielkopolski, 63-400, Poland
  • GSK Investigational Site
    Piekary Slaskie, 41-940, Poland
  • GSK Investigational Site
    Wilkowice, 43-365, Poland
  • GSK Investigational Site
    Chelyabinsk, 454034, Russian Federation
  • GSK Investigational Site
    Kazan, 420015, Russian Federation
  • GSK Investigational Site
    Kemerovo, 650000, Russian Federation
  • GSK Investigational Site
    Moscow, 115093, Russian Federation
  • GSK Investigational Site
    Moscow, 115446, Russian Federation
  • GSK Investigational Site
    Moscow, 125367, Russian Federation
  • GSK Investigational Site
    Yaroslavl, 150003, Russian Federation
  • GSK Investigational Site
    Alicante, 03114, Spain
  • GSK Investigational Site
    Barakaldo (Vizcaya), 48903, Spain
  • GSK Investigational Site
    Cáceres, 10003, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Pozuelo De Alarcón/Madrid, 28223, Spain
  • GSK Investigational Site
    San Sebastián, 20014, Spain
  • GSK Investigational Site
    Valencia, 46015, Spain
  • GSK Investigational Site
    Cherkassy, 18009, Ukraine
  • GSK Investigational Site
    Ivano-Frankivsk, 76018, Ukraine
  • GSK Investigational Site
    Kharkiv, 61035, Ukraine
  • GSK Investigational Site
    Kiev, 03680, Ukraine
  • GSK Investigational Site
    Kyiv, 04107, Ukraine
09

References and documents

Publications

  • Agusti A, de Teresa L, De Backer W, Zvarich MT, Locantore N, Barnes N, Bourbeau J, Crim C. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Eur Respir J. 2014 Mar;43(3):763-72. doi: 10.1183/09031936.00054213. Epub 2013 Oct 10. PubMed 24114969 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 1 year 9 months after primary completion. A results delay was requested in Apr 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2011
First posted
Apr 27, 2011
Start
Feb 1, 2011
Primary completionActual
Oct 1, 2011
CompletionActual
Oct 19, 2011
Results delay requested
Apr 26, 2012
Results first posted
Jul 30, 2013
Last update
Aug 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01342913
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 27, 2011
Start date
Feb 1, 2011
Primary completion
Oct 1, 2011
Completion
Oct 19, 2011
Results posted
Jul 30, 2013
Last update
Aug 31, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone furoate

Start the discussion